Literature DB >> 25552702

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.

Christian Koenecke1, Gudrun Göhring2, Liesbeth C de Wreede3, Anja van Biezen4, Christof Scheid5, Liisa Volin6, Johan Maertens7, Jürgen Finke8, Nicolaas Schaap9, Marie Robin10, Jakob Passweg11, Jan Cornelissen12, Dietrich Beelen13, Michael Heuser14, Theo de Witte9, Nicolaus Kröger15.   

Abstract

The aim of this study was to determine the impact of the revised 5-group International Prognostic Scoring System cytogenetic classification on outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for Blood and Marrow Transplantation database. A total of 903 patients had sufficient cytogenetic information available at stem cell transplantation to be classified according to the 5-group classification. Poor and very poor risk according to this classification was an independent predictor of shorter relapse-free survival (hazard ratio 1.40 and 2.14), overall survival (hazard ratio 1.38 and 2.14), and significantly higher cumulative incidence of relapse (hazard ratio 1.64 and 2.76), compared to patients with very good, good or intermediate risk. When comparing the predictive performance of a series of Cox models both for relapse-free survival and for overall survival, a model with simplified 5-group cytogenetics (merging very good, good and intermediate cytogenetics) performed best. Furthermore, monosomal karyotype is an additional negative predictor for outcome within patients of the poor, but not the very poor risk group of the 5-group classification. The revised International Prognostic Scoring System cytogenetic classification allows patients with myelodysplastic syndromes to be separated into three groups with clearly different outcomes after stem cell transplantation. Poor and very poor risk cytogenetics were strong predictors of poor patient outcome. The new cytogenetic classification added value to prediction of patient outcome compared to prediction models using only traditional risk factors or the 3-group International Prognostic Scoring System cytogenetic classification. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552702      PMCID: PMC4349280          DOI: 10.3324/haematol.2014.116715

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

1.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  V Runde; T de Witte; R Arnold; A Gratwohl; J Hermans; A van Biezen; D Niederwieser; M Labopin; M P Walter-Noel; A Bacigalupo; N Jacobsen; P Ljungman; E Carreras; H J Kolb; C Aul; J Apperley
Journal:  Bone Marrow Transplant       Date:  1998-02       Impact factor: 5.483

2.  Penalized likelihood in Cox regression.

Authors:  P J Verweij; H C Van Houwelingen
Journal:  Stat Med       Date:  1994 Dec 15-30       Impact factor: 2.373

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.

Authors:  T J Nevill; H C Fung; J D Shepherd; D E Horsman; S H Nantel; H G Klingemann; D L Forrest; C L Toze; H J Sutherland; D E Hogge; S C Naiman; A Le; D A Brockington; M J Barnett
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

5.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

Authors:  T de Witte; S Suciu; G Verhoef; B Labar; E Archimbaud; C Aul; D Selleslag; A Ferrant; P Wijermans; F Mandelli; S Amadori; U Jehn; P Muus; M Boogaerts; R Zittoun; A Gratwohl; H Zwierzina; A Hagemeijer; R Willemze
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Authors:  Matteo G Della Porta; Emilio Paolo Alessandrino; Andrea Bacigalupo; Maria Teresa van Lint; Luca Malcovati; Cristiana Pascutto; Michele Falda; Massimo Bernardi; Francesco Onida; Stefano Guidi; Anna Paola Iori; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Emanuele Angelucci; Rosi Oneto; Francesco Ripamonti; Paolo Bernasconi; Alberto Bosi; Mario Cazzola; Alessandro Rambaldi
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

8.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

9.  Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party.

Authors:  Francesco Onida; Ronald Brand; Anja van Biezen; Michel Schaap; Peter A von dem Borne; Johan Maertens; Dietrich W Beelen; Enric Carreras; Emilio P Alessandrino; Liisa Volin; Jürgen H E Kuball; Angela Figuera; Jorge Sierra; Jürgen Finke; Nicolaus Kröger; Theo de Witte
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

10.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

View more
  18 in total

Review 1.  Myelodysplastic Syndromes: Updates and Nuances.

Authors:  Kim-Hien T Dao
Journal:  Med Clin North Am       Date:  2017-03       Impact factor: 5.456

2.  CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Authors:  Roni Tamari; Stephen S Chung; Esperanza B Papadopoulos; Ann A Jakubowski; Patrick Hilden; Sean M Devlin; Jenna D Goldberg; Miguel-Angel Perales; Doris M Ponce; Craig S Sauter; Molly A Maloy; Dara Y Herman; Virginia Klimek; James W Young; Richard J O'Reilly; Sergio A Giralt; Hugo Castro-Malaspina
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

Review 3.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

Authors:  Theo de Witte; David Bowen; Marie Robin; Luca Malcovati; Dietger Niederwieser; Ibrahim Yakoub-Agha; Ghulam J Mufti; Pierre Fenaux; Guillermo Sanz; Rodrigo Martino; Emilio Paolo Alessandrino; Francesco Onida; Argiris Symeonidis; Jakob Passweg; Guido Kobbe; Arnold Ganser; Uwe Platzbecker; Jürgen Finke; Michel van Gelder; Arjan A van de Loosdrecht; Per Ljungman; Reinhard Stauder; Liisa Volin; H Joachim Deeg; Corey Cutler; Wael Saber; Richard Champlin; Sergio Giralt; Claudio Anasetti; Nicolaus Kröger
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

4.  Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Authors:  M Robin; R Porcher; W Zinke-Cerwenka; A van Biezen; L Volin; G Mufti; C Craddock; J Finke; C Richard; J Passweg; A Peniket; J Maertens; G Sucak; T Gedde-Dahl; A Vitek; A Nagler; D Blaise; D Beelen; N Maillard; R Schwerdtfeger; T de Witte; N Kroger
Journal:  Bone Marrow Transplant       Date:  2016-11-07       Impact factor: 5.483

5.  Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.

Authors:  Rupa Narayan; Jonathan E Benjamin; Omid Shah; Lu Tian; Keri Tate; Randall Armstrong; Bryan J Xie; Robert Lowsky; Ginna Laport; Robert S Negrin; Everett H Meyer
Journal:  Biol Blood Marrow Transplant       Date:  2019-04-03       Impact factor: 5.742

6.  Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

Authors:  Marcelo C Pasquini; Mei-Jie Zhang; Bruno C Medeiros; Philippe Armand; Zhen-Huan Hu; Taiga Nishihori; Mahmoud D Aljurf; Görgün Akpek; Jean-Yves Cahn; Mitchell S Cairo; Jan Cerny; Edward A Copelan; Abhinav Deol; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Biju George; Vikas Gupta; Gregory A Hale; Rammurti T Kamble; Thomas R Klumpp; Hillard M Lazarus; Selina M Luger; Jane L Liesveld; Mark R Litzow; David I Marks; Rodrigo Martino; Maxim Norkin; Richard F Olsson; Betul Oran; Attaphol Pawarode; Michael A Pulsipher; Muthalagu Ramanathan; Ran Reshef; Ayman A Saad; Wael Saber; Bipin N Savani; Harry C Schouten; Olle Ringdén; Martin S Tallman; Geoffrey L Uy; William A Wood; Baldeep Wirk; Waleska S Pérez; Minoo Batiwalla; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-29       Impact factor: 5.742

7.  Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Authors:  Brian C Shaffer; Kwang Woo Ahn; Zhen-Huan Hu; Taiga Nishihori; Adriana K Malone; David Valcárcel; Michael R Grunwald; Ulrike Bacher; Betty Hamilton; Mohamed A Kharfan-Dabaja; Ayman Saad; Corey Cutler; Erica Warlick; Ran Reshef; Baldeep Mona Wirk; Mitchell Sabloff; Omotayo Fasan; Aaron Gerds; David Marks; Richard Olsson; William Allen Wood; Luciano J Costa; Alan M Miller; Jorge Cortes; Andrew Daly; Tamila L Kindwall-Keller; Rammurti Kamble; David A Rizzieri; Jean-Yves Cahn; Robert Peter Gale; Basem William; Mark Litzow; Peter H Wiernik; Jane Liesveld; Bipin N Savani; Ravi Vij; Celalettin Ustun; Edward Copelan; Uday Popat; Matt Kalaycio; Richard Maziarz; Edwin Alyea; Ron Sobecks; Steven Pavletic; Martin Tallman; Wael Saber
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

8.  Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Authors:  Eric J Duncavage; Meagan A Jacoby; Gue Su Chang; Christopher A Miller; Natasha Edwin; Jin Shao; Kevin Elliott; Joshua Robinson; Haley Abel; Robert S Fulton; Catrina C Fronick; Michelle O'Laughlin; Sharon E Heath; Kimberly Brendel; Raya Saba; Lukas D Wartman; Matthew J Christopher; Iskra Pusic; John S Welch; Geoffrey L Uy; Daniel C Link; John F DiPersio; Peter Westervelt; Timothy J Ley; Kathryn Trinkaus; Timothy A Graubert; Matthew J Walter
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

9.  Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report.

Authors:  Tatsuyoshi Ikenoue; Yoshiyuki Furumatsu; Tetsuya Kitamura
Journal:  Oxf Med Case Reports       Date:  2021-05-24

10.  Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.

Authors:  Marios Dimitriou; Petter S Woll; Teresa Mortera-Blanco; Mohsen Karimi; David C Wedge; Helen Doolittle; Iyadh Douagi; Elli Papaemmanuil; Sten Eirik W Jacobsen; Eva Hellström-Lindberg
Journal:  Oncotarget       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.